-
Third domestically developed ECMO machine receives approval
2023-02-24
The National Medical Products Administration said on Thursday it has granted emergency authorization to the third homegrown extracorporeal membrane oxygenation machine.
-
Spread of COVID-19 epidemic in China basically ended, expert says
2023-02-24
The spread of the COVID-19 epidemic has basically ended in China, though it is not completely over, a senior health expert said on Thursday.
-
China steadily enters new phase of COVID response: spokesperson
2023-02-24
China has steadily entered a new phase of COVID-19 prevention and control, which was downgraded under the management of Class B infectious diseases, a National Health Commission spokesperson said Thursday.
-
Simnotrelvir Tablets/Ritonavir Tablets(co-packaged) and Deuremidevir Hydrobromide Tablets for treating COVID-19 infection approved for marketing with conditions
2023-01-29
Recently, the class 1 innovative drug Simnotrelvir Tablets/Ritonavir Tablets(co-packaged) (Chinese trade name: 先诺欣) of Simcere Pharmaceutical Group Limited and Deuremidevir Hydrobromide Tablets (Chinese trade name: 民得维) of Shanghai Wangshi Biomedicine Technology Inc. are approved for marketing with conditions by China NMPA through emergency review and approval procedure in accordance with the relevant provisions of special review and approval prescribed in the Drug Administration Law.
-
Second Biosimilar Tocilizumab Injection approved for marketing
2023-01-18
Recently, the Tocilizumab Injection (Chinese trade name: 安维泰) of Livzon Pharmaceutical Group Inc. is approved for marketing by China NMPA. This drug is the second Tocilizumab Injection biosimilar approved in China, which is indicated for rheumatoid arthritis.
-
Biosimilar Tocilizumab Injection approved for marketing
2023-01-16
Recently, the Tocilizumab Injection (Chinese trade name:施瑞立) of Bio-Thera Solutions, Ltd. is approved for marketing by China NMPA.
